Your browser doesn't support javascript.
loading
Features and management of men with pN1 cM0 prostate cancer after radical prostatectomy and lymphadenectomy: a systematic review of population-based evidence.
Laine, Charles; Gandaglia, Giorgio; Valerio, Massimo; Heidegger, Isabel; Tsaur, Igor; Olivier, Jonathan; Ceci, Francesco; van den Bergh, Roderick C N; Kretschmer, Alexander; Thibault, Constance; Chiu, Peter K; Tilki, Derya; Kasivisvanathan, Veeru; Preisser, Felix; Zattoni, Fabio; Fankhauser, Christian; Kesch, Claudia; Puche-Sanz, Ignacio; Moschini, Marco; Pradere, Benjamin; Ploussard, Guillaume; Marra, Giancarlo.
Afiliação
  • Laine C; Department of Urology, Institut Mutualiste Montsouris, Paris, France.
  • Gandaglia G; Department of Urology, San Raffaele Hospital and Scientific Institute, Milan, Italy.
  • Valerio M; Department of Urology, Lausanne University Hospital, Lausanne, Switzerland.
  • Heidegger I; Department of Urology, Medical University Innsbruck, Innsbruck, Austria.
  • Tsaur I; Department of Urology and Pediatric Urology, Mainz University Medicine, Mainz, Germany.
  • Olivier J; Department of Urology, University Hospital Lille, Lille, France.
  • Ceci F; Department of Nuclear Medicine, European Institute of Oncology, Milan, Italy.
  • van den Bergh RCN; Department of Urology, Antonius Hospital, Utrecht, The Netherlands.
  • Kretschmer A; Department of Urology, Ludwig-Maximilians-University of Munich, Munich, Germany.
  • Thibault C; Department of Medical Oncology, Hôpital Européen Georges-Pompidou, Paris, France.
  • Chiu PK; Division of Urology, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China.
  • Tilki D; Department of Urology, Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
  • Kasivisvanathan V; Department of Urology, University College London, London, UK.
  • Preisser F; Department of Urology, Goethe University, Frankfurt, Germany.
  • Zattoni F; Urology Unit, Santa Maria della Misericordia University Hospital, Udine, Italy.
  • Fankhauser C; Department of Urology, Cantonal Hospital of Lucerne, Lucerne, Switzerland.
  • Kesch C; West German Cancer Center; Department of Urology, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany.
  • Puche-Sanz I; Department of Urology, Bio-Health Research Institute, Hospital Universitario Virgen de las Nieves, University of Granada Granada, Spain.
  • Moschini M; Department of Urology, San Raffaele Hospital and Scientific Institute, Milan, Italy.
  • Pradere B; Department of Urology, Medical University of Vienna, Vienna, Austria.
  • Ploussard G; Department of Urology, La Croix du Sud Hospital, Toulouse, France and Institut Universitaire du Cancer Toulouse - Oncopole, Toulouse, France.
  • Marra G; Department of Urology, Institut Mutualiste Montsouris, Paris, France.
Curr Opin Urol ; 32(1): 69-84, 2022 01 01.
Article em En | MEDLINE | ID: mdl-34812201
ABSTRACT
PURPOSE OF REVIEW To investigate the features and optimal management of pN+ cM0 prostate cancer (PCa) according to registry-based studies. RECENT

FINDINGS:

Up to 15% of PCa patients harbor lymph node invasion (pN+) at radical prostatectomy plus lymph node dissection. Nonetheless, the optimal management strategy in this setting is not well characterized.

SUMMARY:

We performed a systematic review including n = 13 studies. Management strategies comprised 13 536 men undergoing observation, 11 149 adjuvant androgen deprivation therapy (aADT), 7,075 adjuvant radiotherapy (aRT) +aADT and 705 aRT. Baseline features showed aggressive PCa in the majority of men. At a median follow-up ranging 48-134months, Cancer-related death was 5% and overall-mortality 16.6%. aADT and aRT alone had no cancer-specific survival or overall survival advantages over observation only and over not performing aRT, respectively. aADT plus aRT yielded a survival benefit compared to observation and aADT, which in one study, were limited to certain intermediate-risk categories. Age, Gleason, Charlson score, positive surgical margins, pathological stage, and positive nodes number, but not prostate specific antigen, were most relevant prognostic factors. Our work further confirmed pN+ PCa is a multifaceted disease and will help future research in defining its optimal management based on different risk categories to maximize survival and patient's quality of life.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Antagonistas de Androgênios Tipo de estudo: Observational_studies / Prognostic_studies / Systematic_reviews Limite: Humans / Male Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Antagonistas de Androgênios Tipo de estudo: Observational_studies / Prognostic_studies / Systematic_reviews Limite: Humans / Male Idioma: En Ano de publicação: 2022 Tipo de documento: Article